ZHONGSHENGYAOYE(SZ:002317) Sou Hu Cai Jing·2025-12-24 20:06Core Viewpoint - The company has received approval for a new product, which is expected to enhance its product line in the respiratory system and complement its existing innovative drugs [2]. Group 1: Company Performance - As of December 24, 2025, the stock price of Zhongsheng Pharmaceutical (002317) closed at 19.46 yuan, down 0.05%, with a turnover rate of 7.28%, trading volume of 554,100 hands, and a transaction amount of 1.08 billion yuan [1]. - On the same day, the net outflow of main funds was 2.8084 million yuan, while the net inflow of speculative funds was 21.1941 million yuan, and the net outflow of retail funds was 18.3858 million yuan [1][3]. Group 2: Product Development - The company has obtained the drug registration certificate for Ambroxol Hydrochloride Oral Solution, with approved specifications of 10ml:30mg and 100ml:0.3g, classified as a Category 4 chemical drug, equivalent to passing the consistency evaluation for generic drugs [2]. - The Ambroxol Hydrochloride Oral Solution is indicated for the treatment of viscous phlegm and difficulty in expectoration caused by acute and chronic bronchitis, and it is listed as a Class B drug under medical insurance [2]. - The projected sales for this product in Chinese public hospitals and urban retail pharmacies are 710.84 million yuan for 2022, 817.66 million yuan for 2023, and 849.53 million yuan for 2024 [2].